Evidence Library
Filter by drug, type, year, and open access.
Showing 51–100 of 427 results
- Effect of antidepressants on ejaculation dysfunction in patients with depression and anxiety: a systematic review and network meta-analysis — Andrology (2025)• Drug: imipraminePMID
- Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis — The British Journal of Psychiatry (2025)• Drug: imipraminePMID
- Effect of mood stabilizers on cognition in bipolar disorder: A systematic review and meta-analysis of randomized controlled trials — Journal of Affective Disorders (2025)• Drug: lithiumPMID
- Efficacy of Different Combination Therapies for Mania in Bipolar Disorder: A systematic review and meta-analysis — Brain and Behavior (2025)• Drug: lithiumPMID
- The efficacy and safety of trazodone for sleep problems in depressive patients — Psychopharmacology (2025)• Drug: trazodoneDOI
- Therapeutic Drug Monitoring in Psychiatry (Review) — Frontiers/PMC (2024)• Drug: clozapineOpen accessPMCID
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: citalopramDOIPMID
- The efficacy of lamotrigine in bipolar disorder: a systematic review and meta-analysis — Bipolar Disorders (2024)• Drug: lamotrigineDOIPMID
- Residual effects of medications for sleep disorders on driving performance — European Neuropsychopharmacology (2024)• Drug: estazolamDOI
- Residual effects of medications for sleep disorders on driving performance — European Neuropsychopharmacology (2024)• Drug: flurazepamDOI
- Residual effects of medications for sleep disorders on driving performance — European Neuropsychopharmacology (2024)• Drug: quazepamDOI
- Residual effects of medications for sleep disorders on driving performance — European Neuropsychopharmacology (2024)• Drug: temazepamDOI
- Residual effects of medications for sleep disorders on driving performance — European Neuropsychopharmacology (2024)• Drug: triazolamDOI
- Initiating Aripiprazole Lauroxil: Post Hoc Analysis of Safety and Tolerability of 1-Day and 21-Day Regimens — Journal of Clinical Psychiatry (2024)• Drug: aripiprazole-lauroxilDOIPMID
- Fluphenazine decanoate prescribing information — DailyMed (2024)• Drug: fluphenazine-decanoateOpen access
- Physiologically-Based Pharmacokinetic Modeling and In Vitro-In Vivo Correlation of TV-46000 (Risperidone LAI): Prediction from Dog to Human — Pharmaceutics (2024)• Drug: risperidone-uzedyOpen accessDOIPMIDPMCID
- Use of an injection of aripiprazole given once every 2 months (Abilify Asimtufii) in people with bipolar I disorder: a plain language summary — Therapeutic Advances in Psychopharmacology (2024)• Drug: aripiprazole-asimtufiiOpen accessDOIPMIDPMCID
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: amoxapineDOIPMID
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: isocarboxazidDOIPMID
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: nefazodoneDOIPMID
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: olanzapine-fluoxetineDOIPMID
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: selegilineDOIPMID
- Monoamine oxidase inhibitors: Seriously underused in the treatment of major depression — Acta Psychiatrica Scandinavica (2024)• Drug: selegilineDOI
- Monoamine oxidase inhibitors: Seriously underused in the treatment of major depression — Acta Psychiatrica Scandinavica (2024)• Drug: selegiline-transdermalDOI
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: trimipramineDOIPMID
- Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a network meta-analysis. — The Lancet Psychiatry (2023)• Drug: lurasidoneDOIPMID
- Pharmacological treatments in panic disorder in adults: a network meta-analysis — Cochrane Database of Systematic Reviews (2023)• Drug: alprazolamOpen accessDOIPMIDPMCID
- 2023 American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults — Journal of the American Geriatrics Society (2023)• Drug: diphenhydramineDOIPMID
- 2023 American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults — Journal of the American Geriatrics Society (2023)• Drug: promethazineDOIPMID
- In vivo characterization of Perseris and compositionally equivalent formulations — International Journal of Pharmaceutics (2023)• Drug: risperidone-perserisDOIPMID
- Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis — JAMA (2023)• Drug: naltrexoneOpen accessDOIPMIDPMCID
- Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis — JAMA (2023)• Drug: acamprosateOpen accessDOIPMIDPMCID
- Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis — JAMA (2023)• Drug: disulfiramOpen accessDOIPMIDPMCID
- Nicotine receptor partial agonists for smoking cessation — Cochrane Database of Systematic Reviews (2023)• Drug: vareniclineOpen accessDOIPMIDPMCID
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: amoxapineOpen access
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: isocarboxazidOpen access
- Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology — Journal of Psychopharmacology (2023)• Drug: lorazepamDOI
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: nefazodoneOpen access
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: olanzapine-fluoxetineOpen access
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: selegilineOpen access
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: selegiline-transdermalOpen access
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: tranylcypromineOpen access
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: trimipramineOpen access
- Zuranolone for the Treatment of Postpartum Depression — The American Journal of Psychiatry (2023)• Drug: zuranolonePMID
- GLP-1 receptor agonists for atypical antipsychotic-related metabolic dysfunctions (systematic review) — Experimental and Therapeutic Medicine (2023)• Drug: semaglutide-ozempicOpen accessPMIDPMCID
- GLP-1 receptor agonists for atypical antipsychotic-related metabolic dysfunctions (systematic review) — Experimental and Therapeutic Medicine (2023)• Drug: semaglutide-wegovyOpen accessPMIDPMCID
- GLP-1 receptor agonists for atypical antipsychotic-related metabolic dysfunctions (systematic review) — Experimental and Therapeutic Medicine (2023)• Drug: tirzepatide-mounjaroOpen accessPMIDPMCID
- GLP-1 receptor agonists for atypical antipsychotic-related metabolic dysfunctions (systematic review) — Experimental and Therapeutic Medicine (2023)• Drug: tirzepatide-zepboundOpen accessPMIDPMCID
- Pharmacological treatment for bipolar mania: network meta-analysis of RCTs. — Molecular Psychiatry (2022)• Drug: quetiapineOpen accessDOIPMIDPMCID
- Pharmacological treatments for antipsychotic-induced hyperprolactinemia: network meta-analysis. — Translational Psychiatry (2022)• Drug: risperidoneOpen accessDOIPMIDPMCID